Media Contact:Ilana Ostrin212 328 3769iostrin@hemophilia.orgThe National Hemophilia Foundation applauds Congressional Representatives Donald McEachin (D-VA), Rodney Davis (R-IL), Bonnie Watson Coleman (D-NJ), Bobby Rush (D-IL),…
Community member and NHF supporter Jim Christensen has been granted the Rosen Award from Ameritas. With this award, NHF received a $20,000 grant in Christensen's honor, which will support he organization’s work to cure inheritable blood…
The Indiana Hemophilia & Thrombosis Center and Partners in Bleeding Disorders Education Program have announced a new education program designed for physicians who practice at federally funded hemophilia treatment centers (HTCs) in the U.S. The…
People living with rare and chronic bleeding disorders such as hemophilia and von Willebrand disease often rely on high-cost specialty medications that do not have generic alternatives. The National Bleeding Disorders Foundation opposes health…
Media Contact:Ilana Ostrin212 328 3769iostrin@hemophilia.org“NHF applauds the CDC’s recommendation of the Pfizer-BioNTech COVID-19 vaccine for children 5 to 11 years of age. Evidence-based studies have long shown that children…
During this session, participants will learn from a panel of community members who share their experiences on various reproductive health topics. The panel will discuss topics such as family planning, relationship/fertility obstacles, shared…
During this session participants will learn from a panel of healthcare providers, including a genetics counselor, obstetrician/gynecologist and hematologist. The panel will discuss topics such as genetic counseling, preparing for pregnancy and birth…
NHF Statement In Response to New Michigan Law:
“The National Hemophilia Foundation thanks Governor Whitmer for taking steps to address the public health crisis that is period poverty. For girls, women, and all people who menstruate or have the…
November 5, 2021 – On Tuesday, November 4, the U.S. Food and Drug Administration (FDA) placed the Pfizer/Sangamo hemophilia A gene therapy program, including the pivotal phase 3 AFFINE study(NCT04370054), with giroctocogene…
Objective:
To examine the frequency and methods used to screen patients for substance use and behavioral health disorders in Hemophilia Treatment Centers (HTC). We hypothesized that inconsistencies in methods utilized and…